VJHemOnc is committed to improving our service to you

SOHO 2020 | BCL-2 frontline therapy in CLL

VJHemOnc is committed to improving our service to you

Michael Hallek

Michael Hallek, MD, University Hospital of Cologne, Cologne, Germany, explores why BCL-2 inhibition is a superior front-line treatment for patients with chronic lymphocytic leukemia (CLL) and highlights the benefit of combination therapy in CLL therapy, including agents such as venetoclax, obinutuzumab and ibrutinib for this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter